FRD Friedman Industries stock gains 414 percent following the release of its Q3 2024 earnings report Gilead Sciences GILD Valuation Implications of Expanded Kymera Therapeutics Collaboration and Kymeras FDA Fast Track Designation Vertex Pharmaceuticals Incorporated VRTX Price Target Raised by RBC Amid Positive Regulatory Milestones and Biotech Sector Tailwinds What EPS forecast for Infinite IEAGR State Street SPDR SP Biotech ETF XBI Investment Case Analysis and Peer Benchmarking for 2026